Inside Nephrology: A Weekly Review
Nefrologia
Cardio-Renal-Metabolic Breakthroughs: What Nephrologists Must Know Now
This episode explores the game-changing role of diabetes medications in preventing heart failure and improving outcomes across cardiovascular, metabolic, and kidney systems. We review a meta-analysis on semaglutide, new insights on SGLT2 inhibitors, and the evolving concept of Cardiovascular-Kidney-Metabolic (CKM) syndrome — all with a focus on what this means for nephrology practice.
Bibliography
- Gao H et al. Front Endocrinol (Lausanne). 2025;16:1562815. doi: 10.3389/fendo.2025.1562815
- O’Hara DV, Jardine MJ. Diabetes Obes Metab. 2025;27(7):3598–3606. doi: 10.1111/dom.16385
- Wang Y et al. Front Endocrinol (Lausanne). 2025;16:1554637. doi: 10.3389/fendo.2025.1554637
- Wu L et al. J Immunother Cancer. 2025;13(6):e011271. doi: 10.1136/jitc-2024-011271
- Darwish D et al. Cells. 2025;14(12):919. doi: 10.3390/cells14120919
